Faisal Ghiath Sukhtian, Director at Outlook Therapeutics, Inc. (OTLK), bought 18,000 shares at $1.40 ($25K) on 2021-12-02, disclosed to the SEC on 2021-12-02.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| OTLK | BUY | 2022-10-11 | $39K | — | Filing → |
| OTLK | BUY | 2021-04-20 | $18K | — | Filing → |
| OTLK | BUY | 2020-09-17 | $7K | — | Filing → |